

**ACADEMIC SUPPORT SERVICES AGREEMENT****AGREEMENT NUMBER: 21-8568**

This agreement is entered into between the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Madison's **Carbone Cancer Center** (*hereafter University*) and the **The Medical College of Wisconsin, Inc.** (*hereafter Contractor or MCW*):

**CONTRACTOR INFORMATION**

**Contractor's Name (as shown on W9):** The Medical College of Wisconsin, Inc.  
**Address:** 8701 Watertown Plank Road Hub 5386  
**City / State / Zip:** Milwaukee, WI 53226  
**Contact Name / E-Mail:** Jon B. Mayer / [jmayer@mcw.edu](mailto:jmayer@mcw.edu)

**CONTRACT TERM****Start Date:** December 1, 2020**End Date:** November 30, 2022**COMPENSATION INFORMATION**

Fee not to exceed (total amount to be paid for the full contract term) \$ 150,000.00

- Indirects not permitted.
- Fee will be paid on the purchase order.

**PAYMENT TERMS: (NOTE: Payment will be made 30 days upon receipt of an invoice from the Contractor. Contractor must invoice according to the terms of the contract.)**

The University will transfer fees to Contractor in one payment upon execution of this contract and receipt of invoice.

**DEPARTMENT CONTACT INFORMATION**

**Name:** Mark McClintock  
**Telephone:** 608-262-3925  
**E-mail:** [mrmcclin@wisc.edu](mailto:mrmcclin@wisc.edu)

**PROJECT SCOPE**

The University's collaboration with Contractor is part of the University's Centene Pancreas Cancer Collaborative program. MCW's clinical and basic science research with pancreas cancer includes senior investigators, Susan Tsai, MD and Douglas Evans, MD. MCW pancreas cancer research program includes additional investigators, including William Hall, MD, a radiation oncologist, Mandana Kamgar, a medical oncologist who are both developing investigator-initiated trials, and two basic scientists, Dr. Subramaniam Malarkannan, PhD, a cancer immunologist, and Dr. Jong-In Park, PhD, who is an expert in signaling and cancer metabolism. The funds from the Centene Pancreas Cancer Collaborative will be used to support ongoing translational research from the Park and Malarkannan lab. Work from Dr. Park's lab will further develop preclinical data on the efficacy of combinatorial therapy using tyrosine kinase inhibitors and metabolic targeting agents, such as Mito-Q. Work from Dr. Malarkannan's lab be focused on immunologic changes in the tumor microenvironment related with radiation therapy. Additional funds, if available, may be utilized to develop investigator-initiated trials in pancreatic cancer.

*Evaluation of Progress Funded projects will compete for funds for each subsequent year. Future funding is dependent on progress, funds available, and scientific priorities. By design, these are higher risk than average projects. We anticipate that a project may exit this funding mechanism based on its success or failure. Graduation of a successful project, as measured by achieving substantial external funding, is the preferred exit strategy. Experimental evidence that a concept is not feasible or failure of a project to make progress despite good faith effort are acceptable termination criteria for a given project.*

**PROJECT DELIVERABLES**

**Overall Deliverables and Metrics Standard Benchmarks of scientific productivity will help measure the success or failure of the existing projects and the collaborative science including scientific publications, impact of those publications, external or internal grant funding. Deliverables from this research award include:**

- Final written summary and progress report after one year from start.
- Presentation to UWCCC Pancreas Cancer Research Collaborative.
- Participation in UWCCC led strategic planning for pancreas cancer research in WI.
- Dr. Susan Tsai is an Advisory Committee Member of Pancreas Cancer Centene Collaborative and will work with UWCCC Advisory members (Dr. Howard Bailey is acting Chair) to create a 5-year strategic plan.

**DEBARMENT**

Federal Executive Order (E.O.) 12549 "Debarment" requires that all contractors receiving individual awards, using federal funds, and all subrecipients certify that the organization and its principals are not debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any Federal department or agency from doing business with the Federal Government. By signing this document you certify that your organization and its principals are not debarred. Failure to comply or attempts to edit this language may disqualify your bid. Information on debarment is available at the following websites: [www.sam.gov](http://www.sam.gov) and <https://acquisition.gov/far/index.html> see section 52.209-6.

Your signature certifies that neither you nor your principal is presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction by any federal department or agency.

**SUPPLIER DIVERSITY**

Minority, Women Owned, and Service Disabled Veteran Owned businesses are encouraged to register for State of Wisconsin certified status by going to the following website and following the instructions that are provided there: <http://www.doa.state.wi.us/Divisions/Enterprise-Operations/Supplier-Diversity-Program>

For Federal Small Business Administration (SBA) status pertaining to small, disadvantaged, veteran owned, service disabled, woman owned, or HUBZone business designations please visit: <https://www.sba.gov/contracting/getting-started-contractor/make-sure-you-meet-sba-size-standards>

**CONTRACTOR ACCEPTANCE**

I agree to the standard terms and conditions attached to this agreement. I verify that I am duly qualified and willing to perform the services as an independent contractor. The fees under this Agreement do not exceed my normal and customary rate. I am not a current University of Wisconsin System employee.


**FOR THE BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM**

**FOR THE CONTRACTOR**

**University of Wisconsin-Madison**

**The Medical College of Wisconsin, Inc.**

DocuSigned by:  
  
18AC0A7E58C4476...  
Signature

DocuSigned by:  
  
82116735160C4AF...  
Signature

Lori Voss

April A. Haverty, MPE, JD  
Name Printed or Typed

Director of Purchasing  
UW Madison Division of Business Services  
6/1/2021  
Date

Director, Grants and Contracts  
Title  
4/30/2021  
Date  
414-955-8563  
Phone Number

Agreement No: **21-8568**

**Search Results** Save Edit Search Criteria Export Share

3 Projects Search Criteria Fiscal Year: 2023, 2022, 2021, 2020, 2019 Principal Investigator (PI): Jung In Park

Projects		Publications	Patents	Clinical Studies	News & More					
T	Act Project	Year	Sub	Principal Investigator(s)/ Project Leader(s)	Organization	Fiscal Year	Admin IC	Funding IC	FY Total Cost by IC	Similar Projects
	<b>The Role of Mortalin in Thyroid Cancer</b>									
1	BB1CA269452-81A1			PARK, JONG-IN	MEDICAL COLLEGE OF WISCONSIN	2023	NCI	NCI	\$436,322	<a href="#">View</a>
	<b>Mechanisms of MEK/ERK growth arrest signaling</b>									
5	BB1CA138441-1B			PARK, JONG-IN	MEDICAL COLLEGE OF WISCONSIN	2020	NCI	NCI	\$308,000	<a href="#">View</a>
	<b>Mechanisms of MEK/ERK growth arrest signaling</b>									
5	BB1CA138441-89			PARK, JONG-IN	MEDICAL COLLEGE OF WISCONSIN	2019	NCI	NCI	\$336,105	<a href="#">View</a>

**Filters**

- Fiscal Years
- Org Names
- Agencies
- States
- Countries
- Principal Investigators